First Mercantile Trust Co. continued to hold its position in shares of Sanofi (NYSE:SNY) during the second quarter, Holdings Channel reports. The fund owned 7,500 shares of the company’s stock at the end of the second quarter. First Mercantile Trust Co.’s holdings in Sanofi were worth $359,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Harbour Capital Advisors LLC acquired a new position in shares of Sanofi during the first quarter worth about $113,000. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in shares of Sanofi by 6,188.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock worth $171,000 after buying an additional 3,713 shares during the period. Proficio Capital Partners LLC increased its position in shares of Sanofi by 95.8% in the first quarter. Proficio Capital Partners LLC now owns 4,265 shares of the company’s stock worth $210,000 after buying an additional 2,087 shares during the period. Huntington National Bank increased its position in shares of Sanofi by 3.4% in the first quarter. Huntington National Bank now owns 4,455 shares of the company’s stock worth $202,000 after buying an additional 147 shares during the period. Finally, Boyd Watterson Asset Management LLC OH acquired a new position in shares of Sanofi during the first quarter worth about $213,000. Hedge funds and other institutional investors own 9.90% of the company’s stock.
Sanofi (SNY) opened at 48.08 on Friday. The company has a market cap of $120.75 billion, a P/E ratio of 11.36 and a beta of 0.88. Sanofi has a 1-year low of $36.81 and a 1-year high of $50.24. The stock’s 50 day moving average price is $47.84 and its 200 day moving average price is $46.35.
Sanofi (NYSE:SNY) last issued its quarterly earnings data on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The company had revenue of $8.66 billion during the quarter, compared to analyst estimates of $8.71 billion. The business’s revenue was down 2.3% compared to the same quarter last year. On average, equities analysts anticipate that Sanofi will post $3.26 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “First Mercantile Trust Co. Has $359,000 Stake in Sanofi (SNY)” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.com-unik.info/2017/08/18/first-mercantile-trust-co-has-359000-stake-in-sanofi-sny.html.
A number of brokerages have issued reports on SNY. Cowen and Company restated a “market perform” rating and issued a $52.00 price objective (up previously from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. BidaskClub upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Berenberg Bank downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a research note on Thursday, April 20th. Finally, Argus upped their price objective on Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, June 9th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company’s stock. Sanofi has an average rating of “Hold” and an average price target of $54.00.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
What are top analysts saying about Sanofi? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi and related companies.